Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways: Resistance to Targeted Anti-Cancer Therapeutics, cartea 15
Editat de Yosef Yarden, Moshe Elkabetsen Limba Engleză Hardback – 10 apr 2018
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (1) | 1092.43 lei 6-8 săpt. | |
| Springer International Publishing – 2 feb 2019 | 1092.43 lei 6-8 săpt. | |
| Hardback (1) | 1099.35 lei 6-8 săpt. | |
| Springer International Publishing – 10 apr 2018 | 1099.35 lei 6-8 săpt. |
Din seria Resistance to Targeted Anti-Cancer Therapeutics
- 5%
Preț: 718.10 lei - 5%
Preț: 1107.21 lei - 5%
Preț: 1096.10 lei - 5%
Preț: 1100.30 lei - 5%
Preț: 1093.35 lei - 5%
Preț: 1103.22 lei - 5%
Preț: 1093.88 lei - 5%
Preț: 1096.10 lei - 5%
Preț: 841.00 lei - 5%
Preț: 715.91 lei - 5%
Preț: 714.83 lei - 5%
Preț: 1093.88 lei - 5%
Preț: 712.25 lei - 5%
Preț: 1024.59 lei - 5%
Preț: 723.57 lei - 5%
Preț: 721.19 lei - 5%
Preț: 721.19 lei - 5%
Preț: 726.68 lei - 5%
Preț: 723.21 lei - 5%
Preț: 717.73 lei
Preț: 1099.35 lei
Preț vechi: 1157.22 lei
-5% Nou
Puncte Express: 1649
Preț estimativ în valută:
210.38€ • 218.31$ • 175.85£
210.38€ • 218.31$ • 175.85£
Carte tipărită la comandă
Livrare economică 15-29 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319679303
ISBN-10: 3319679309
Pagini: 257
Ilustrații: XX, 242 p. 22 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.54 kg
Ediția:1st ed. 2018
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics
Locul publicării:Cham, Switzerland
ISBN-10: 3319679309
Pagini: 257
Ilustrații: XX, 242 p. 22 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.54 kg
Ediția:1st ed. 2018
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics
Locul publicării:Cham, Switzerland
Cuprins
Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.
Notă biografică
Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.
Textul de pe ultima copertă
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Caracteristici
Comprehensively covers the multiplicity and diversity of mechanisms underlying resistance to the currently approved drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors playing driver or survival functions in cancer Examines specific targets and the cognate drugs Evaluates molecular modes of innate and evolving resistance